Cetuximab + Tislelizumab + Chemotherapy in the Treatment of Unresectable LA HNSCC
NCT06978829
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
42
Enrollment
OTHER
Sponsor class
Conditions
LA HNSCC
Interventions
DRUG:
TP + Cetuximab + Tislelizumab
Sponsor
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University